Details of Disease

General Information of Disease (ID: DISLKUNL)

• Disease Name: Heart arrhythmia
• Synonyms: heart rhythm disease; disorder of cardiac conduction; disease of cardiac conduction; conduction disease of heart; cardiac conduction disorder; cardiac conduction disease
• Disease Class: BC65: Genetic cardiac arrhythmia
• Definition: A disease that has its basis in the disruption of the heart's electrical conduction system.
• Disease Hierarchy:
  DISVO1I5: Cardiac disease
  DISLKUNL: Heart arrhythmia
• ICD Code:
  ICD-11: ICD-11: BC65
  ICD-10: ICD-10: I49, I49.8
  Expand ICD-11: 'BC9Z
  Expand ICD-10: 'I47.0; 'I49; 'I49.4; 'I49.8; 'I49.9; 'R00.0; 'R00.1

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Edetate disodium	DMZ8NZP	Approved	Small molecular drug	[1]
Lorcainide	DM63VRX	Approved	Small molecular drug	[1]
Moricizine	DMOMBJW	Approved	Small molecular drug	[2]
Pilsicainide	DMZ65K8	Approved	Small molecular drug	[1]
Pirmenol	DMBCYF5	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AOP-200704	DMXGV7M	Phase 2	NA	[3]
HBI-3000	DM74ZKN	Phase 2	NA	[4]

This Disease is Treated as An Indication in 27 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bethanidine	DMJMHNL	Withdrawn from market	Small molecular drug	[5]
Encainide	DMK0GHV	Withdrawn from market	Small molecular drug	[6]
Bidisomide	DM47ZHW	Discontinued in Phase 3	Small molecular drug	[7]
H-345/52	DMLXNQJ	Discontinued in Phase 2	NA	[8]
Pentisomide	DMTGBPW	Discontinued in Phase 2	Small molecular drug	[9]
Risotilide	DMNRGB7	Discontinued in Phase 2	Small molecular drug	[10]
GW-473178	DMRQVI9	Discontinued in Phase 1	NA	[11]
KT-362	DM74BK8	Discontinued in Phase 1	Small molecular drug	[12]
AR-H050642	DMHX6AU	Terminated	NA	[13]
AWD-23-111	DMD8ZM1	Terminated	NA	[14]
AZD-3118	DMTYSK5	Terminated	NA	[15]
Barucainide	DMTMS3L	Terminated	Small molecular drug	[16]
Berlafenone	DMQA4JU	Terminated	Small molecular drug	[17]
CDE-5498	DMVHTQI	Terminated	NA	[18]
Cordil	DMQESM7	Terminated	NA	[19]
GE-68	DMZF9CY	Terminated	Small molecular drug	[20]
HOE-694	DML0B97	Terminated	Small molecular drug	[21]
ICI-181037	DM0XU4P	Terminated	Small molecular drug	[22]
NC-1006	DMD2KGR	Terminated	NA	[23]
Org-20781	DM95QG2	Terminated	NA	[24]
Recainam	DMDC2E8	Terminated	Small molecular drug	[25]
RS-2135	DMFJ0KC	Terminated	Small molecular drug	[26]
S-1389	DMDQGFR	Terminated	Small molecular drug	[27]
SLV-322	DMV5S61	Terminated	NA	[28]
SNAP-5089	DMROJEN	Terminated	Small molecular drug	[29]
TJN-505	DM3LZVE	Terminated	Small molecular drug	[30]
WAY-123223	DMMOS8G	Terminated	Small molecular drug	[31]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
44-Bu	DMLUDL4	Investigative	NA	[32]
NS-1643	DMT97KV	Investigative	Small molecular drug	[33]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 10 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
TTR	OTAFXQRA	Strong	Autosomal dominant	[34]
ACTN2	OT9FOLD7	Limited	Autosomal dominant	[34]
ANK2	OTWB4R1Y	Limited	Autosomal dominant	[34]
FLNC	OT3F8J6Y	Limited	Autosomal dominant	[34]
GJA5	OTRMZVO6	Limited	Autosomal dominant	[34]
KCNK17	OTG2NEZM	Limited	Unknown	[34]
TBX3	OTM64N7K	Limited	Autosomal dominant	[34]
CLCA2	OTF191LZ	Moderate	Autosomal dominant	[34]
TBX5	OT70PISV	Moderate	Autosomal dominant	[34]
EMD	OTR8ZANE	Strong	X-linked	[34]

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GJA5	TTFQKZ7	Limited	Autosomal dominant	[34]
TTR	TTPOYU7	Strong	Autosomal dominant	[34]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7244).
• [3] ClinicalTrials.gov (NCT01313143) A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT01235156) Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions. U.S. National Institutes of Health.
• [5] FDA Approved Drug Products from FDA Official Website. 1981. Application Number: (ANDA) 008102.
• [6] New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. Mayo Clin Proc. 1987 Nov;62(11):1033-50.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000174)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009708)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000271)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002381)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015039)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000337)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013356)
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005585)
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026718)
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000197)
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000213)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020444)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001241)
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001596)
• [21] Effect of Hoe 694, a novel Na(+)-H+ exchange inhibitor, on intracellular pH regulation in the guinea-pig ventricular myocyte. Br J Pharmacol. 1996 Aug;118(8):1905-12.
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001161)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002921)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003350)
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000248)
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001212)
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000214)
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019508)
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 498).
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007726)
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001818)
• [32] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [33] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7660).
• [34] The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.